Edesa Biotech
EDSAEdesa Biotech Inc. (NASDAQ: EDSA) is a clinical-stage biopharmaceutical company based in Canada. The company's primary business focus is the development and commercialization of treatments for inflammatory and immune-related diseases. As a publicly traded entity, its strategic operations are centered on advancing therapeutic candidates through clinical trials to address significant unmet medical needs. The company's key therapeutic areas include dermatology and acute care. Its most advanced clinical asset is EB05 (paridiprubart), a monoclonal antibody designed to inhibit Toll-like Receptor 4 (TLR4) signaling, which is being investigated as a potential host-directed therapy for acute lung injury associated with diseases like COVID-19. In dermatology, Edesa is developing EB01 (daniluromer), a non-steroidal anti-inflammatory drug, as a topical treatment for chronic allergic contact dermatitis. Edesa Biotech's pipeline also includes EB06, a monoclonal antibody targeting CXCL10 for vitiligo. The company's research and development activities are supported by clinical data from various trial phases, and its corporate strategy involves pursuing regulatory pathways for its lead candidates. The company's financial position and operational progress are disclosed through its filings with the U.S. Securities and Exchange Commission.
EDSA · Stock Price
Historical price data
About
Edesa Biotech Inc. (NASDAQ: EDSA) is a clinical-stage biopharmaceutical company based in Canada. The company's primary business focus is the development and commercialization of treatments for inflammatory and immune-related diseases. As a publicly traded entity, its strategic operations are centered on advancing therapeutic candidates through clinical trials to address significant unmet medical needs. The company's key therapeutic areas include dermatology and acute care. Its most advanced clinical asset is EB05 (paridiprubart), a monoclonal antibody designed to inhibit Toll-like Receptor 4 (TLR4) signaling, which is being investigated as a potential host-directed therapy for acute lung injury associated with diseases like COVID-19. In dermatology, Edesa is developing EB01 (daniluromer), a non-steroidal anti-inflammatory drug, as a topical treatment for chronic allergic contact dermatitis. Edesa Biotech's pipeline also includes EB06, a monoclonal antibody targeting CXCL10 for vitiligo. The company's research and development activities are supported by clinical data from various trial phases, and its corporate strategy involves pursuing regulatory pathways for its lead candidates. The company's financial position and operational progress are disclosed through its filings with the U.S. Securities and Exchange Commission.